Gefitinib is also active for carcinomatous meningitis in NSCLC

被引：32

作者：

Kim, MK

Lee, KH

Lee, JK

Choi, JH

Hyun, MS

机构：

[1] Yeungnam Univ, Coll Med, Dept Internal Med, Taegu, South Korea

[2] Yeungnam Univ, Coll Med, Dept Diagnost Radiol, Taegu, South Korea

[3] Yeungnam Univ, Coll Med, Dept Pathol, Taegu, South Korea

来源：

LUNG CANCER | 2005年 / 50卷 / 02期

关键词：

carcinomatous meningitis; gefitinib;

D O I：

10.1016/j.lungcan.2005.05.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Carcinomatous meningitis (CM) and spinal cord metastases (SCM) are uncommon, yet fatal complication for patients with non-small cell lung cancer (NSCLC). Gefitinib, developed to inhibit the tyrosine kinase of the epidermal growth factor receptor (EGFR), represents the first new treatment modality for NSCLC to emerge from the last decade. Furthermore, it is an attractive option for lung cancer patients with CNS metastasis because of its mild toxicity profile, but there are not much data on the ability of gefitinib to cross the blood-brain barrier. And also, the response of patients with CM and SCM to gefitinib has rarely been reported on. We report here a good response to gefitinib by a heavily pretreated 59-year-old man with CM and SCM. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：265 / 269

页数：5

共 14 条

[1] Tyrosine kinase inhibitors-ZD1839 (Iressa) [J].

Arteaga, CL ;

Johnson, DH .

CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :491-498

[2] Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) [J].

Cappuzzo, F ;

Ardizzoni, A ;

Soto-Parra, H ;

Gridelli, C ;

Maione, P ;

Tiseo, M ;

Calandri, C ;

Bartolini, S ;

Santoro, A ;

Crinò, L .

LUNG CANCER, 2003, 41 (02) :227-231

[3] Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity [J].

Chiu, CH ;

Tsai, CM ;

Chen, YM ;

Chiang, SC ;

Liou, JL ;

Perng, RP .

LUNG CANCER, 2005, 47 (01) :129-138

[4]

Glantz MJ, 1998, CANCER, V82, P733, DOI 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO

[5]

2-Z

[6] Leptomeningeal carcinomatosis [J].

Grossman, SA ;

Krabak, MJ .

CANCER TREATMENT REVIEWS, 1999, 25 (02) :103-119

[7]

Heimberger AB, 2002, CLIN CANCER RES, V8, P3496

[8]

Larson DA, 2005, CANC PRINCIPLES PRAC, P2333

[9] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[10] Brain metastasis responding to gefitinib alone [J].

Poon, ANY ;

Ho, SSM ;

Yeo, W ;

Mok, TSK .

ONCOLOGY, 2004, 67 (02) :174-178

← 1 2 →